Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

(PACB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2021 11/24/2021 11/26/2021 11/29/2021 11/30/2021 Date
22.87(c) 23.39(c) 23.32(c) 23.06(c) 23.21(c) Last
2 946 079 2 394 964 1 407 216 2 728 106 3 074 176 Volume
+0.84% +2.27% -0.30% -1.11% +0.65% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 131 M - -
Net income 2021 -189 M - -
Net cash position 2021 422 M - -
P/E ratio 2021 -25,3x
Yield 2021 -
Sales 2022 186 M - -
Net income 2022 -243 M - -
Net cash position 2022 413 M - -
P/E ratio 2022 -20,9x
Yield 2022 -
Capitalization 5 120 M 5 120 M -
EV / Sales 2021 35,9x
EV / Sales 2022 25,3x
Nbr of Employees 412
Free-Float 93,9%
More Financials
Company
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company’s has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include the... 
More about the company
Ratings of Pacific Biosciences of California, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
11/30PacBio Names Jason Kang as Vice President and General Manager for Asia-Pacific Region
AQ
11/19PACIFIC BIOSCIENCES OF CALIFORNIA, I : Change in Directors or Principal Officers (form 8-K..
AQ
11/19PacBio Grants Equity Incentive Award to New Employee
AQ
11/18PacBio and ARUP Laboratories Collaborate in a Study to Improve Rare Disease Diagnosis
AQ
11/18Pacbio and ARUP Laboratories Collaborate in a Study to Improve Rare Disease Diagnosis
CI
11/16Pacific Biosciences of California Launches Product For Genomic Monitoring of COVID Vari..
MT
11/16PacBio Launches HiFiViral SARS-CoV-2 Kit and Microbial Whole Genome Sequencing Enhancem..
AQ
11/16PacBio Launches Hifiviral SARS-CoV-2 Kit and Microbial Whole Genome Sequencing Enhancem..
CI
11/11PacBio to Present at Upcoming Investor Conferences
AQ
11/05PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Management's Discussion and Analysis of Financ..
AQ
11/02PACIFIC BIOSCIENCES : Q3 Earnings Snapshot
AQ
11/02Pacific Biosciences of California, Inc. Provides Earnings Guidance for the Full Year of..
CI
11/02PacBio Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/02Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Reports Q3 Loss $-0.23
MT
11/02Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Posts Q3 Revenue $34.9M
MT
More news
News in other languages on PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
11/16La société californienne Pacific Biosciences lance un produit pour la surveillance géno..
11/02Pacific Biosciences of California, Inc. fournit des prévisions de résultats pour l'ense..
11/02Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA affiche un chiffre d'affaires d..
09/17VENTE D'INITIÉS : Pacific Biosciences Of California
02/10SoftBank invertirá US$900 millones en Pacific Biosciences
More news
Analyst Recommendations on PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
More recommendations
Chart PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Duration : Period :
Pacific Biosciences of California, Inc. Technical Analysis Chart | PACB | US69404D1081 | MarketScreener
Technical analysis trends PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 23,21 $
Average target price 45,20 $
Spread / Average Target 94,7%
EPS Revisions
Managers and Directors
Christian O. Henry President, Chief Executive Officer & Director
Susan G. Kim Chief Financial Officer
John F. Milligan Chairman
Stephen W. Turner Chief Technology Officer
Jonas Korlach Chief Scientific Officer